Physician profile
Arvind Chaudhry
NPI 1750336236
$71,079.19
in general payments reported to CMS, 2019-2025
100 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $7,010 · 2021: $5,125 · 2022: $10K · 2023: $7,743 · 2024: $5,100 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $2,960 · Honoraria: $2,700 · Long Term Medical Supply Or Device Loan: $1,263 · Education: $1,250 · Travel and Lodging: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,853.74 |
| Consulting Fee | $2,960.00 |
| Honoraria | $2,700.00 |
| Long Term Medical Supply Or Device Loan | $1,263.36 |
| Education | $1,250.24 |
| Travel and Lodging | $1,135.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $13,096.36 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $11,771.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $5,859.32 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $5,484.14 | 2019-2025 | Erleada, Tecvayli, Darzalex |
| Genentech USA, INC. | $3,191.49 | 2019-2025 | Tecentriq, Alecensa, Rozlytrek |
| Novartis Pharmaceuticals Corporation | $3,032.18 | 2019-2025 | Kisqali |
| Astellas Pharma US INC | $2,095.55 | 2019-2025 | Cresemba, Padcev, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $2,014.57 | 2019-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $1,821.55 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,550.45 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Amgen INC. | $1,216.12 | 2019-2023 | Blincyto, Lumakras, Nplate |
| Merck Sharp & Dohme LLC | $1,199.06 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $1,110.56 | 2019-2025 | Reblozyl, Sprycel, Opdualag |
| Seagen INC. | $989.84 | 2019-2025 | Adcetris, Padcev |
| Genzyme Corporation | $929.73 | 2019-2025 |
Show all 98 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $922.06 | 2019-2025 | Venclexta |
| Siemens Medical Solutions USA, INC. | $864.64 | 2022 | |
| Eisai INC. | $863.00 | 2019-2025 | |
| Lilly USA, LLC | $833.77 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $828.82 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Takeda Pharmaceuticals U.S.A., INC. | $590.17 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Emd Serono, INC. | $559.24 | 2019-2025 | Bavencio |
| Regeneron Healthcare Solutions, INC. | $516.63 | 2019-2025 | Libtayo, Lynozyfic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.01 | 2019-2024 | Gilotrif |
| Tersera Therapeutics LLC | $431.30 | 2021-2025 | Quzyttir, Xermelo, Zoladex |
| Sanofi-Aventis U.S. LLC | $408.64 | 2019-2023 | |
| Glaxosmithkline, LLC. | $374.21 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Sobi, INC | $360.60 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $338.08 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Array Biopharma INC | $331.20 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Blueprint Medicines Corporation | $298.31 | 2020-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $297.42 | 2019-2025 | Zepzelca |
| Aveo Pharmaceuticals, INC. | $275.94 | 2021-2025 | Fotivda |
| Aurobindo Pharma USA, INC. | $263.71 | 2019-2020 | |
| Daiichi Sankyo INC. | $231.71 | 2019-2025 | Datroway, Enhertu |
| Acrotech Biopharma INC. | $220.75 | 2021-2025 | Beleodaq, Ryzneuta, Folotyn |
| Gilead Sciences, INC. | $206.00 | 2019-2025 | Trodelvy |
| Taiho Oncology, INC. | $197.86 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $187.32 | 2020-2025 | Oxlumo |
| Agios Pharmaceuticals, INC. | $185.79 | 2019-2025 | Pyrukynd |
| Beigene USA, INC. | $173.54 | 2020-2025 | Brukinsa |
| Beone Medicines USA, INC. | $168.78 | 2025 | Brukinsa, Tevimbra |
| Iovance Biotherapeutics, INC. | $130.99 | 2025 | Amtagvi |
| Kite Pharma, INC. | $127.54 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $124.64 | 2023-2025 | Orgovyx |
| Pharmaessentia USA Corporation | $123.06 | 2023 | Besremi |
| Puma Biotechnology, INC. | $122.26 | 2019-2025 | |
| Immunomedics, INC. | $119.28 | 2020 | |
| Myriad Genetic Laboratories, INC. | $118.93 | 2020-2024 | Precisetumor, Myrisk |
| Foundation Medicine, INC. | $116.48 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $113.75 | 2019-2021 | |
| Dova Pharmaceuticals | $105.01 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $101.34 | 2020-2022 | |
| Spectrum Pharmaceuticals INC. | $100.82 | 2019-2025 | Rolvedon |
| Acceleron Pharma, INC. | $100.19 | 2020-2021 | |
| Eusa Pharma (US) LLC | $99.95 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $99.20 | 2021-2025 | |
| Heron Therapeutics, INC. | $98.70 | 2019-2023 | Cinvanti |
| Deciphera Pharmaceuticals INC. | $96.00 | 2021-2023 | Qinlock |
| Stemline Therapeutics INC. | $95.47 | 2024-2025 | Orserdu |
| Dendreon Pharmaceuticals LLC | $95.34 | 2020-2025 | Provenge |
| Springworks Therapeutics, INC. | $94.92 | 2024-2025 | Ogsiveo |
| Epizyme, INC. | $91.81 | 2021-2022 | |
| Mirati Therapeutics, INC. | $83.61 | 2023-2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $82.72 | 2023-2025 | Monoferric |
| Morphosys, US INC. | $79.20 | 2021-2023 | Monjuvi |
| Telix Pharmaceuticals | $78.31 | 2023-2024 | Illuccix |
| Janssen Pharmaceuticals, INC | $77.71 | 2019-2020 | |
| US Oncology Corporate, INC. | $76.91 | 2023 | |
| Tesaro, INC. | $75.32 | 2019 | |
| Azurity Pharmaceuticals, INC. | $66.70 | 2025 | Danziten, Vivimusta |
| Helsinn Therapeutics (U.S.), INC. | $65.76 | 2019-2025 | Valchlor, Akynzeo |
| Recordati_rare_diseases_inc. | $65.12 | 2023-2025 | Enjaymo, Panhematin |
| Accord Healthcare, INC. | $62.66 | 2024-2025 | |
| G1 Therapeutics, INC. | $61.36 | 2022 | |
| Sirtex Medical INC | $58.64 | 2019-2020 | |
| Coherus Oncology, INC. | $58.24 | 2020-2025 | Loqtorzi |
| Myovant Sciences INC. | $56.44 | 2021-2022 | |
| Cti Biopharma Corp. | $56.35 | 2023 | Vonjo |
| Lexicon Pharmaceuticals, INC. | $53.55 | 2019-2020 | |
| Genentech, INC. | $53.45 | 2025 | Tecentriq |
| Syndax Pharmaceuticals, INC. | $48.88 | 2025 | |
| Secura Bio, INC. | $47.93 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $45.17 | 2020-2022 | |
| Adaptive Biotechnologies Corporation | $44.31 | 2021-2023 | Clonoseq |
| Asd Specialty Healthcare, LLC | $39.24 | 2023 | |
| Alexion Pharmaceuticals, INC. | $38.95 | 2020-2021 | |
| Tg Therapeutics, INC. | $37.98 | 2021 | |
| Janssen Scientific Affairs, LLC | $37.52 | 2019 | |
| Amag Pharmaceuticals, INC. | $36.04 | 2021 | |
| Clovis Oncology, INC. | $32.00 | 2020-2021 | |
| Immunocore Limited | $31.95 | 2025 | Kimmtrak |
| Caris Mpi, INC. | $31.34 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $30.95 | 2025 | Carvykti |
| Verastem, INC. | $30.33 | 2019 | |
| Btg International INC. | $28.95 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $28.07 | 2024 | |
| Genmab U.S., INC. | $27.17 | 2025 | Epkinly |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,422.07 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.